E3 Ubiquitin Ligases CBL-B and C-CBL Downregulate PD-L1 in EGFR Wild-Type Non-Small Cell Lung Cancer

FEBS Letters - United States
doi 10.1002/1873-3468.12985
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

MA21.02 Identification of an E2 Ubiquitin Conjugase CDC34 That Competes With E3 Ligase C-CBL to Stabilize EGFR and Promotes Lung Carcinogenesis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

C-CBL E3 Ubiquitin Ligase Is Overexpressed in Cutaneous T-Cell Lymphoma: Its Inhibition Promotes Activation-Induced Cell Death

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2015English

PD-1 and PD-L1 Expression in Molecularly Selected Non-Small-Cell Lung Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2014English

P073 CBL-B Predicts Prognosis of NSCLC Patients and Affects PD-L1 Expression in A549

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Progress in the Study on PD-L1 Inhibitor in the Treatment of EGFR-Mutant Non-Small Cell Lung Cancer

Clinical Oncology and Research
2020English

PD‑L1 Expression Is Associated With Advanced Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2016English

P3.17-01 PD-L1 Expression, EGFR Mutations and ALK Expression in Non-Small Cell Lung Cancer (NSCLC) Patients From Brazil

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

The Role of E3 Ubiquitin Ligase CBL Proteins in Interleukin-2-Induced Jurkat T-Cell Activation

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2013English

E3 Ubiquitin Ligases in Cancer and Their Pharmacological Targeting

2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy